Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer
17
×
life sciences
17
×
national blog main
boston blog main
san francisco blog main
boston top stories
national top stories
san francisco top stories
biotech
clinical trials
national
texas blog main
texas top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
cancer drugs
loxo oncology
amgen
blueprint medicines
keytruda
pfizer
bristol-myers squibb
colorectal cancer
deals
What
cancer
17
×
drug
medicine
medicines
fda
ipo
new
annual
clinical
genetic
oncology
pharmaceutical
research
society
targets
today
approval
approved
bio
biotech
black
blueprint
cash
companies
conference
esmo
european
immunotherapy
known
lines
medical
meeting
patients
potential
proteins
reach
revolution
risks
roundup
seen
Language
unset
Current search:
cancer
×
" life sciences "
×
cancer
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
BioAffinity Seeking $5M for Cancer Diagnostic, Adds Board Member